Marieke van Son

19 GENERAL INTRODUCTION AND THESIS OUTLINE 17. Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, et al. Added Value of Multiparametric Magnetic Res- onance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. The Journal of urology. 2018;200(5):1041-7. 18. Feng TS, Sharif-Afshar AR, Wu J, Li Q, Luthringer D, Saouaf R, et al. Multipara- metric MRI Improves Accuracy of Clin- ical Nomograms for Predicting Extra- capsular Extension of Prostate Cancer. Urology. 2015;86(2):332-7. 19. Chang JH, Lim Joon D, Nguyen BT, Hiew CY, Esler S, Angus D, et al. MRI scans sig- nificantly change target coverage deci- sions in radical radiotherapy for prostate cancer. Journal of medical imaging and radiation oncology. 2014;58(2):237-43. 20. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-51. 21. Egevad L, Delahunt B, Srigley JR, Sa- maratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading. APMIS : acta pathologica, microbiologica, et immuno- logica Scandinavica. 2016;124(6):433-5. 22. Ahmed HU, Hu Y, Carter T, Arumain- ayagam N, Lecornet E, Freeman A, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. The Journal of urology. 2011;186(2):458-64. 23. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Com- prehensive Cancer Network : JNCCN. 2019;17(5):479-505. 24. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Pros- tate Cancer. Part 1: Screening, Diagno- sis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-29. 25. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969-74. 26. Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019. BJU international. 2019;124(1):1. 27. Serrano NA, Anscher MS. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classifica- tion System and Its Impact on Treatment Recommendations. Oncology (Williston Park, NY). 2016;30(3):229-36. 28. SandaMG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/ SUO Guideline. Part I: Risk Stratification, SharedDecisionMaking, andCareOptions. The Journal of urology. 2018;199(3):683-90. 29. van Kalmthout LWM, vanMelick HHE, La- valaye J, Meijer RP, Kooistra A, de Klerk JMH, et al. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomogra- phy/Computerized Tomography for Pri- mary Staging of Prostate Cancer. The Journal of urology. 2020;203(3):537-45. 30. Corfield J, Perera M, Bolton D, Lawrent- schuk N. (68)Ga-prostate specific mem- brane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a system- atic review. World journal of urology. 2018;36(4):519-27. 31. Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P, et al. Metastases in normal-sized pelvic lymph nodes: detection with diffu- sion-weighted MR imaging. Radiology. 2014;273(1):125-35. 1